Bg pattern

TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Tenkasi 1200mg powder for concentrate for solution for infusion

oritavancin

Read all of this leaflet carefully before you are giventhis medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or nurse.
  • If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Tenkasi and what is it used for
  2. What you need to know before you are given Tenkasi
  3. How Tenkasi is given
  4. Possible side effects
  5. Storage of Tenkasi
  6. Contents of the pack and other information

1. What is Tenkasi and what is it used for

Tenkasi is an antibiotic that contains the active substance oritavancin. Oritavancin is a type of antibiotic (a lipoglycopeptide antibiotic) that can kill or stop the growth of certain bacteria.

Tenkasi is used to treat skin and soft tissue infections.

It is only used to treat adult patients.

Tenkasi can only be used to treat infections caused by bacteria known as Gram-positive bacteria. In the case of mixed infections where the presence of other types of bacteria is suspected, your doctor will provide you with other appropriate antibiotics along with Tenkasi.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you are given Tenkasi

You should not be givenTenkasi:

  • if you are allergic to oritavancin or any of the other ingredients of this medicine (listed in section 6).
  • if you are expected to need to be given a medicine to make your blood less thick (unfractionated heparin sodium) in the 5 days (120 hours) following the dose of Tenkasi.

Warnings and precautions

Talk to your doctor or nurse before receiving Tenkasi if:

  • you have ever had an allergic reaction to another glycopeptide antibiotic (such as vancomycin and telavancin)
  • you have had severe diarrhea during or after antibiotic treatment in the past.
  • you have or are suspected to have a bone infection caused by bacteria (osteomyelitis). Your doctor will treat you as necessary
  • You have or are suspected to have a painful accumulation of pus in the skin (abscess). Your doctor will treat you as necessary.

Intravenous infusions of Tenkasi can cause redness of the upper body, hives, itching and/or rash. Infusion-related reactions such as chest pain, chest discomfort, chills, shivers, back pain, neck pain, shortness of breath, abdominal pain, fever, and headache, fatigue, drowsiness that could be symptoms of hypoxia have also been observed. If you experience reactions of this type, your doctor may decide to stop or slow down the infusion.

Tenkasi may interfere with laboratory tests that measure blood clotting and may produce a false reading.

Although antibiotics, including Tenkasi, fight certain bacteria, they may not be active against other bacteria or fungi, which may continue to grow. This is called overgrowth. Your doctor will monitor you for this and treat you if necessary.

After you are given Tenkasi, you may develop a new infection in another area of the skin. Your doctor should monitor you for this and treat you as necessary.

Children and adolescents

Tenkasi should not be used in children or adolescents under 18 years of age.

Using Tenkasi with other medicines

Tell your doctor if you are using, have recently used, or might use any other medicines.

If you are going to be given a medicine to make your blood less thick called unfractionated heparin, tell your doctor if you have received Tenkasi in the last 5 days (120 hours).

It is especially important that you tell your doctor if you are using medicines that prevent blood from clotting (oral anticoagulants, e.g. coumarin anticoagulants). Tenkasi may interfere with laboratory tests or self-tests that measure blood clotting (INR), and may cause a false reading up to 12 hours after infusion.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

You should not be given this medicine during pregnancy unless your doctor considers that the benefit is greater than the risk to the baby.

Driving and using machines

Tenkasi can make you feel dizzy, so it may affect your ability to drive or use machines.

Tenkasi contains cyclodextrins

Tenkasi 1200 mg contains 2400 mg of hydroxypropylbetadex in each vial, equivalent to 9.6 mg/ml.

3. How Tenkasi is given

Tenkasi is available as Tenkasi 1200 mg and Tenkasi 400 mg. The two medicines differ in the amount of oritavancin per vial, the duration of infusion, and the preparation instructions for administration.

Your doctor or nurse will carefully administer Tenkasi 1200 mg by infusion (drip) into a vein.

The recommended dose of Tenkasi is a single infusion of 1200 mg administered into a vein over 1 hour.

If you use more Tenkasithan you should

Your doctor will decide how to treat you, as well as when to stop treatment and monitor for signs of side effects.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor or nurse immediately if you experience an infusion reaction, including any of the following symptoms:

  • redness of the face and upper body, hives, itching and/or rash;
  • wheezing (high-pitched sound when breathing);
  • shortness of breath;
  • swelling around the throat or under the skin that appears in a short period of time;
  • chills or shivers;
  • rapid or weak pulse;
  • chest pain or tightness;
  • Decreased blood pressure (may make you feel weak or dizzy).

Such reactions can be life-threatening.

Other side effects occur with the following frequencies:

Common side effects (may affect up to 1 in 10 people)

  • fewer red blood cells or less hemoglobin than normal;
  • dizziness;
  • headache;
  • feeling sick (nausea) or vomiting;
  • diarrhea;
  • constipation;
  • pain or irritation at the injection site;
  • itching, skin rash;
  • muscle pain;
  • higher amount of liver enzymes (according to blood test results);
  • rapid heartbeat;
  • worsening of an infection or new infection in another area of the skin;
  • swollen and red area of the skin or under the skin with a feeling of heat and pain to the touch;
  • accumulation of pus under the skin.

Uncommon side effects (may affect up to 1 in 100 people)

  • higher than normal levels of eosinophils, a type of white blood cell (eosinophilia);
  • low blood sugar levels;
  • high levels of uric acid in the blood;
  • increased levels of bilirubin in the blood;
  • severe skin rash;
  • hot flushes;
  • inflammation around a tendon (known as tenosynovitis);
  • bone infection caused by bacteria (known as osteomyelitis);
  • low platelet count in the blood below the lower limit of normal (known as thrombocytopenia);
  • Abdominal pain;
  • Chest pain;
  • Fever;
  • Shortness of breath.

Rare side effects (may affect up to 1 in 1,000 people)

  • Headache, fatigue, drowsiness that can be symptoms of low oxygen levels in body tissues (hypoxia);
  • Back pain;
  • Neck pain;
  • Chills;
  • Shivers.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Tenkasi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and on the vial label after EXP. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions.

The diluted solution should be used immediately.

From a microbiological point of view, the medicine should be used immediately. If not used immediately, the storage times and conditions before use are the responsibility of the user and normally should not exceed 4 hours at a temperature of 25 °C and 12 hours at a temperature between 2 °C and 8 °C for Tenkasi diluted in an intravenous infusion bag with glucose 5% or sodium chloride 0.9%.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

What is in Tenkasi

  • The active substance is oritavancin. The vial contains oritavancin diphosphate equivalent to 1200 mg of oritavancin.
  • The other ingredients are hydroxypropylbetadex (see section 2 “Tenkasi contains cyclodextrins”), mannitol, phosphoric acid (for pH adjustment) and sodium hydroxide (for pH adjustment).

Appearance and pack contents

  • Tenkasi is a powder for concentrate for solution for infusion
  • Tenkasi is a white to off-white to pink powder, supplied in a 50 ml glass vial.

Tenkasi is marketed in packs of 1 vial.

Marketing authorisation holder

Menarini International Operations Luxembourg S.A.

1, Avenue de la Gare

L-1611, Luxembourg

Luxembourg

Manufacturer

Biologici Italia Laboratories S.r.l

Via Filippo Serpero 2

20060 Masate (MI)

Italy

You can obtain further information on this medicine from the local representative of the marketing authorisation holder:

België/Belgique/Belgien

Menarini Benelux NV/SA

Tél/Tel: + 32 (0)2 721 4545

Lietuva

UAB “BERLIN-CHEMIE MENARINI BALTIC”

Tel: +370 52 691 947

????????

??????-????/?. ???????? ???????? E???

???.: +359 24540950

Luxembourg/Luxemburg

Menarini Benelux NV/SA

Tél/Tel: + 32 (0)2 721 4545

Ceská republika

Berlin-Chemie/A.Menarini Ceska republika s.r.o.

Tel: +420 267 199 333

Magyarország

Berlin-Chemie/A. Menarini Kft.

Tel.: +36 1799 7320

Danmark

Menarini International Operations Luxembourg S.A.

Tlf: +352 264976

Malta

Menarini International Operations Luxembourg S.A.

Tel: +352 264976

Deutschland

Berlin-Chemie AG

Tel: +49 (0) 30 67070

Nederland

Menarini Benelux NV/SA

Tel: +32 (0)2 721 4545

Eesti

OÜ Berlin-Chemie Menarini Eesti

Tel: +372 667 5001

Norge

Menarini International Operations Luxembourg S.A.

Tlf: +352 264976

Ελλ?δα

MENARINI HELLAS AE

Τηλ: +30 210 8316111-13

Österreich

  • Menarini Pharma GmbH

Tel: +43 1 879 95 85-0

España

Laboratorios Menarini S.A.

Tel: +34-93 462 88 00

Polska

Berlin-Chemie/Menarini Polska Sp. z o.o.

Tel.: +48 22 566 21 00

France

MENARINI France

Tél: +33 (0)1 45 60 77 20

Portugal

  • Menarini Portugal – Farmacêutica, S.A.

Tel: +351 210 935 500

Hrvatska

Berlin-Chemie Menarini Hrvatska d.o.o.

Tel: + 385 1 4821 361

România

Berlin-Chemie A.Menarini S.R.L.

Tel: +40 21 232 34 32

Ireland

  • Menarini Pharmaceuticals Ireland Ltd

Tel: +353 1 284 6744

Slovenija

Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o.

Tel: +386 01 300 2160

Ísland

Menarini International Operations Luxembourg S.A.

Sími: +352 264976

Slovenská republika

Berlin-Chemie / A. Menarini Distribution

Slovakia s.r.o

Tel: +421 2 544 30 730

Italia

  • Menarini - Industrie Farmaceutiche Riunite - s.r.l.Tel: +39-055 56801

Suomi/Finland

Berlin-Chemie/A.Menarini Suomi OY

Puh/Tel: +358 403 000 760

Κ?προς

MENARINI HELLAS AE

Τηλ: +30 210 8316111-13

Sverige

Menarini International Operations Luxembourg S.A.

Tel: +352 264976

Latvija

SIA Berlin-Chemie/Menarini Baltic

Tel: +371 67103210

United Kingdom (NorthernIreland)

  • Menarini Farmaceutica Internazionale S.R.L.

Tel: +44 (0)1628 856400

Date of last revision of this leaflet:09/2023

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.

--------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Tenkasi is intended for intravenous (IV) administration only, after reconstitution and dilution.

Tenkasi should be prepared using aseptic techniques.

There are two medicines that contain oritavancin (Tenkasi 400 mg and Tenkasi 1200 mg) that:

  • Are supplied in different doses of oritavancin.
  • Have a different recommended infusion duration.
  • Have different preparation instructions, including differences in reconstitution, dilution, and compatible diluents.

Follow the recommended instructions for each medicine carefully.

The Tenkasi 1200 mg vial should be reconstituted and diluted to prepare a single intravenous dose of 1200 mg. The powder should be reconstituted with sterile water for injection and the resulting concentrate should be diluted in an intravenous infusion bag with glucose 5% or sodium chloride 9 mg/ml (0.9%) before use. Both the reconstituted solution and the diluted infusion solution should be clear and colorless to pink. Parenteral medicines should be inspected visually for particulate matter after reconstitution. Aseptic techniques should be used for the preparation of Tenkasi.

Reconstitution:

  • 40 ml of sterile water for injection should be added using a sterile syringe to reconstitute the vial to provide a 30 mg/ml solution per vial.
  • To avoid excessive foam formation, it is recommended to add the sterile water for injection carefully, along the wall of the vials.
  • The vial should be gently swirled to avoid foam formation and to ensure that all the Tenkasi powder is completely reconstituted in the solution.

Dilution: For dilution, glucose 5% (D5W) or sodium chloride 9 mg/ml (0.9%) in an intravenous infusion bag should be used.

To dilute:

  • 40 ml should be withdrawn and discarded from a 250 ml intravenous infusion bag of glucose 5% or sodium chloride 0.9%.
  • 40 ml should be withdrawn from the reconstituted vial and added to a 250 ml intravenous infusion bag of glucose 5% or sodium chloride 0.9% to achieve a volume of 250 ml. This provides a concentration of oritavancin of 4.8 mg/ml. For preparation of administration, PP (polypropylene) or PVC (polyvinyl chloride) bags should be used.

The diluted solution should be used immediately.

From a microbiological point of view, the medicine should be used immediately. If not used immediately, the storage times and conditions before use are the responsibility of the user and normally should not exceed 4 hours at a temperature of 25 °C and 12 hours at a temperature between 2 °C and 8 °C for Tenkasi diluted in an intravenous infusion bag with glucose 5% or sodium chloride 0.9%.

Online doctors for TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION

Discuss questions about TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

4.6 (78)
Doctor

Anastasiia Shalko

Family medicine 13 years exp.

Dr. Anastasiia Shalko is a general practitioner with a background in both paediatrics and general medicine. She graduated from Bogomolets National Medical University in Kyiv and completed her paediatric internship at the P.L. Shupyk National Medical Academy of Postgraduate Education. After working as a paediatrician in Kyiv, she relocated to Spain, where she has been practising general medicine since 2015, providing care for both adults and children.Her work focuses on urgent, short-term medical concerns – situations where patients need quick guidance, symptom assessment and clear next steps. She helps people understand whether their symptoms require in-person evaluation, home management or a change in treatment. Common reasons for booking an online consultation include:

  • acute respiratory symptoms (cough, sore throat, runny nose, fever)
  • viral illnesses such as colds and seasonal infections
  • gastrointestinal complaints (nausea, diarrhoea, abdominal pain, gastroenteritis)
  • sudden changes in how a child or adult feels
  • questions about existing treatment and whether adjustments are needed
  • renewal of prescriptions when clinically appropriate

Dr. Shalko works specifically with urgent and short-term problems, providing practical recommendations and helping patients determine the safest next step. She explains symptoms clearly, guides patients through decision-making and offers straightforward medical advice for everyday acute issues.She does not provide long-term management of chronic conditions, ongoing follow-up or comprehensive care plans for complex long-term illnesses. Her consultations are designed for acute symptoms, sudden concerns and situations where timely medical input is important.With clinical experience in both paediatrics and general medicine, Dr. Shalko confidently supports adults and children. Her communication style is clear, simple and reassuring, helping patients feel informed and supported throughout the consultation.

0.0 (15)
Doctor

Lizaveta Trafimchuk Takhvaniuk

Dermatology 10 years exp.

Dr. Lizaveta Trafimchuk Takhvaniuk graduated in Medicine and subsequently specialized in Dermatology and Venereology. She has more than 10 years of clinical experience and is licensed to practice in Spain, where she focuses on the comprehensive diagnosis and treatment of dermatological conditions.

Throughout her education and professional career, Dr. Trafimchuk has gained extensive experience in managing diseases of the skin, hair, and nails, as well as in the diagnosis, treatment, and prevention of sexually transmitted infections (STIs). Her clinical approach is based on evidence-based medicine, combined with personalized care tailored to each patient’s needs.

In her daily practice, she treats a wide range of dermatological conditions, including chronic inflammatory dermatoses such as acne, rosacea, atopic dermatitis, psoriasis, and eczema. She also has experience in treating pigmentation disorders, including melasma, post-inflammatory hyperpigmentation, and dyschromia.

She has developed a particular interest in trichology, treating various types of alopecia, chronic hair loss, and scalp disorders. In addition, she has experience in managing infectious dermatoses of fungal, viral, and bacterial origin, as well as in evaluating benign and suspicious skin lesions, with referral to specialized care when necessary.

With a strong interest in a comprehensive approach to skin health, she also treats scars, post-procedural skin changes, and conditions related to hormonal factors and aging, including those associated with pregnancy, menopause, and age-related skin changes.

Thanks to her experience and continuous professional development, Dr. Trafimchuk provides high-quality medical care that is professional, confidential, and aligned with modern dermatology standards.

0.0 (11)
Doctor

Rita Isabel Calero Garcia

General medicine 2 years exp.

Dr. Rita Isabel Calero Garcia is a physician with extensive experience in emergency medical care, general medicine, and healthcare assistance in various clinical and out-of-hospital settings.

She currently works as a physician at the Canary Islands Emergency Service (Servicio de Urgencias Canario – SUC), where she is responsible for the assessment and care of patients in medical emergency situations, performing the initial diagnosis, patient stabilization, and coordination with hospital services when necessary.

She has also developed her professional activity within the Primary Care Management Service, providing consultations in general medicine. In this setting she is responsible for patient follow-up, management of acute and chronic conditions, as well as health promotion and disease prevention.

She has also worked as a physician in a mobile ICU unit, providing medical assistance in out-of-hospital emergencies, treating critical patients and participating in medicalized patient transport.

In addition, she has collaborated with the Red Cross, participating in healthcare support units, providing medical assistance at events and supporting emergency interventions.

Furthermore, she has provided medical services in the private sector with Salvaser, conducting clinical assessments of patients and providing healthcare services within private medical services.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
0.0 (18)
Doctor

Antonio Cayatte

General medicine 44 years exp.

Dr Antonio Cayatte is a physician in General and Acute Medicine with over 30 years of experience across clinical care, medical research, and education. He offers online consultations for adults with a wide range of symptoms, both acute and chronic. His clinical background includes: 

  • assessment of sudden or unclear symptoms
  • ongoing care for chronic conditions
  • follow-up after hospital discharge
  • interpretation of test results
  • medical support while abroad

Dr Cayatte earned his degree from the University of Lisbon and taught internal medicine at Boston University School of Medicine. He holds active medical registrations in both Portugal and the UK and is a Fellow of the American Heart Association. Consultations are available in English and Portuguese. Patients value his clarity, professionalism, and balanced approach to evidence-based care.

Dr. Antonio Cayatte provides comprehensive care for a broad spectrum of common health concerns, including:

  • Respiratory & ENT: acute bronchitis, concerns related to pneumonia, sinusitis, tonsillitis, ear infections, sore throat conditions, and allergic rhinitis
  • Eye Health: allergic and infectious conjunctivitis, as well as red or irritated eyes
  • Digestive & Urinary: gastroesophageal reflux disease (GERD), gastritis, urinary tract infections, and cystitis
  • Chronic Conditions: hypertension, elevated cholesterol, and structured weight management planning
5.0 (196)
Doctor

Yevgen Yakovenko

General surgery 12 years exp.

Dr. Yevgen Yakovenko is a licensed surgeon and general practitioner in Spain and Germany. He specialises in general, paediatric, and oncological surgery, internal medicine, and pain management. He offers online consultations for adults and children, combining surgical precision with therapeutic support. Dr Yakovenko works with patients across different countries and provides care in Ukrainian, Russian, English, and Spanish.

Areas of medical expertise:

  • Acute and chronic pain: headaches, muscle and joint pain, back pain, abdominal pain, postoperative pain. Identifying the cause, selecting treatment, and creating a care plan.
  • Internal medicine: heart, lungs, gastrointestinal tract, urinary system. Management of chronic conditions, symptom control, second opinions.
  • Pre- and postoperative care: risk assessment, decision-making support, follow-up after surgery, rehabilitation strategies.
  • General and paediatric surgery: hernias, appendicitis, congenital conditions, both planned and urgent surgeries.
  • Injuries and trauma: bruises, fractures, sprains, soft tissue damage, wound care, dressing, referral when in-person care is required.
  • Oncological surgery: diagnosis review, treatment planning, and long-term follow-up.
  • Obesity treatment and weight management: a medical approach to weight loss, including assessment of underlying causes, evaluation of comorbidities, development of a personalised plan (nutrition, physical activity, pharmacotherapy if needed), and ongoing progress monitoring.
  • Imaging interpretation: analysis of ultrasound, CT, MRI, and X-ray results, surgical planning based on imaging data.
  • Second opinions and medical navigation: clarifying diagnoses, reviewing current treatment plans, helping patients choose the best course of action.

Experience and qualifications:

  • 12+ years of clinical experience in university hospitals in Germany and Spain.
  • International education: Ukraine – Germany – Spain.
  • Member of the German Society of Surgeons (BDC).
  • Certified in radiological diagnostics and robotic surgery.
  • Active participant in international medical conferences and research.

Dr Yakovenko explains complex topics in a clear, accessible way. He works collaboratively with patients to analyse health issues and make evidence-based decisions. His approach is grounded in clinical excellence, scientific accuracy, and respect for each individual.

If you are unsure about a diagnosis, preparing for surgery, or want to discuss your test results – Dr Yakovenko will help you evaluate your options and move forward with confidence.

5.0 (56)
Doctor

Anna Biriukova

General medicine 6 years exp.

Dr Anna Biriukova is an internal medicine doctor with clinical experience in cardiology, endocrinology, and gastroenterology. She provides online consultations for adults, offering expert medical support for heart health, hormonal balance, digestive issues, and general internal medicine.

Cardiology – Diagnosis and treatment of:

  • High blood pressure, blood pressure fluctuations, and cardiovascular risk prevention.
  • Chest pain, shortness of breath, arrhythmias (tachycardia, bradycardia, palpitations).
  • Leg swelling, chronic fatigue, reduced exercise tolerance.
  • EKG interpretation, lipid profile evaluation, cardiovascular risk assessment (heart attack, stroke).
  • Post-COVID-19 cardiac monitoring and care.
Endocrinology – Diabetes, thyroid, metabolism:
  • Diagnosis and management of type 1 and type 2 diabetes, and prediabetes.
  • Individual treatment plans including oral medications and insulin therapy.
  • GLP-1 therapy– modern pharmacological treatment for weight management and diabetes control, including drug selection, monitoring, and safety follow-up.
  • Thyroid disorders – hypothyroidism, hyperthyroidism, autoimmune thyroid diseases (Hashimoto’s, Graves’ disease).
  • Metabolic syndrome – obesity, lipid disorders, insulin resistance.
Gastroenterology – Digestive health:
  • Abdominal pain, nausea, heartburn, gastroesophageal reflux (GERD).
  • Stomach and intestinal conditions: gastritis, irritable bowel syndrome (IBS), indigestion.
  • Management of chronic digestive disorders and interpretation of tests (endoscopy, ultrasound, labs).
General internal medicine and preventive care:
  • Respiratory infections – cough, colds, bronchitis.
  • Lab test analysis, therapy adjustments, medication management.
  • Adult vaccinations – planning, contraindications assessment.
  • Cancer prevention – screening strategies and risk assessment.
  • Holistic approach – symptom relief, complication prevention, and quality of life improvement.
Dr Biriukova combines internal medicine with specialist insight, offering clear explanations, personalised treatment plans, and comprehensive care tailored to each patient.

Get TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION Prescription Online

1

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

2

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

3

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

4

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION?

TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.

What is the active substance in TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION?

The active ingredient in TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION is oritavancin. This information helps identify medicines with the same composition but different brand names.

Who manufactures TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION?

TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION is manufactured by Menarini International Operations Luxembourg S.A.. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to TENKASI 1200 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION?

Other medicines with the same active substance (oritavancin) include TENKASI 400 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION, DALBAVANCIN ACCORD 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION, DALBAVANCIN BAXTER 500 mg POWDER FOR CONCENTRATE FOR INFUSION SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media